Pacira Biosciences Inc
F:82P

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
F:82P
Watchlist
Price: 15.5 EUR -9.88% Market Closed
Market Cap: 721.5m EUR

Net Margin

3%
Current
Improving
by 4.9%
vs 3-y average of -1.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
3%
=
Net Income
$21.4m
/
Revenue
$716.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
3%
=
Net Income
€21.4m
/
Revenue
$716.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
Pacira Biosciences Inc
NASDAQ:PCRX
845.1m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
524.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
208.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.2B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.7B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in the United States of America
Percentile
50th
Based on 15 072 companies
50th percentile
3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Pacira Biosciences Inc
Glance View

Market Cap
721.5m EUR
Industry
Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

82P Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
3%
=
Net Income
$21.4m
/
Revenue
$716.8m
What is Pacira Biosciences Inc's current Net Margin?

The current Net Margin for Pacira Biosciences Inc is 3%, which is above its 3-year median of -1.9%.

How has Net Margin changed over time?

Over the last 3 years, Pacira Biosciences Inc’s Net Margin has decreased from 3.2% to 3%. During this period, it reached a low of -18.1% on Jun 30, 2025 and a high of 10.3% on Mar 31, 2024.

Back to Top